193 related articles for article (PubMed ID: 10344150)
21. Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
Adamo V; Ferraro G; Pergolizzi S; Sergi C; Laudani A; Settineri N; Alafaci E; Scimone A; Spano F; Spitaleri G
Oral Oncol; 2004 May; 40(5):525-31. PubMed ID: 15006626
[TBL] [Abstract][Full Text] [Related]
22. Multi-center study of two dose levels of paclitaxel with carboplatin in locally advanced and metastatic non-small cell lung cancer (NSCLC).
Glorieux P; Ortmanns P; Marien S; Degives R; Degraeve D; Potvin M; Grauwels D; Schallier D
Anticancer Res; 2001; 21(2B):1487-94. PubMed ID: 11396237
[TBL] [Abstract][Full Text] [Related]
23. Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
Micha JP; Goldstein BH; Birk CL; Rettenmaier MA; Brown JV
Gynecol Oncol; 2006 Feb; 100(2):437-8. PubMed ID: 16226797
[TBL] [Abstract][Full Text] [Related]
24. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma.
Schrader C; Keussen C; Bewig B; von Freier A; Lins M
Eur J Med Res; 2005 Nov; 10(11):498-501. PubMed ID: 16354605
[TBL] [Abstract][Full Text] [Related]
25. [Paclitaxel (taxol)--a cytostatic drug with a new type of mechanism of action].
Schalhorn B
Med Klin (Munich); 1993 Nov; 88 Suppl 2():4-15. PubMed ID: 7907774
[No Abstract] [Full Text] [Related]
26. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Markman M; Liu PY; Wilczynski S; Monk B; Copeland LJ; Alvarez RD; Jiang C; Alberts D; ;
J Clin Oncol; 2003 Jul; 21(13):2460-5. PubMed ID: 12829663
[TBL] [Abstract][Full Text] [Related]
27. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.
Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ
Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460
[TBL] [Abstract][Full Text] [Related]
28. Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer.
Socinski MA
Oncologist; 1999; 4(5):408-16. PubMed ID: 10551557
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic applications of medicinal plants in the treatment of breast cancer: a review of their pharmacology, efficacy and tolerability.
Mantle D; Lennard TW; Pickering AT
Adverse Drug React Toxicol Rev; 2000 Aug; 19(3):223-40. PubMed ID: 11059361
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells.
Ahn HJ; Kim YS; Kim JU; Han SM; Shin JW; Yang HO
J Cell Biochem; 2004 Apr; 91(5):1043-52. PubMed ID: 15034938
[TBL] [Abstract][Full Text] [Related]
31. A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Ferrari AC; Chachoua A; Singh H; Rosenthal M; Taneja S; Bednar M; Mandeli J; Muggia F
Cancer; 2001 Jun; 91(11):2039-45. PubMed ID: 11391583
[TBL] [Abstract][Full Text] [Related]
32. Taxol reactions.
Price KS; Castells MC
Allergy Asthma Proc; 2002; 23(3):205-8. PubMed ID: 12125509
[TBL] [Abstract][Full Text] [Related]
33. Protein nanoparticles as drug carriers in clinical medicine.
Hawkins MJ; Soon-Shiong P; Desai N
Adv Drug Deliv Rev; 2008 May; 60(8):876-85. PubMed ID: 18423779
[TBL] [Abstract][Full Text] [Related]
34. Delayed seizure associated with paclitaxel-Cremophor el in a patient with early-stage breast cancer.
O'Connor TL; Kossoff E
Pharmacotherapy; 2009 Aug; 29(8):993-6. PubMed ID: 19637953
[TBL] [Abstract][Full Text] [Related]
35. Hypersensitivity reactions in paclitaxel treatment of ovarian cancer patients.
Lehoczky O; Bagaméri A; Udvary J; Pulay T
J Obstet Gynaecol; 2002 May; 22(3):312-3. PubMed ID: 12521509
[No Abstract] [Full Text] [Related]
36. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.
Kim SH; Juhnn YS; Song YS
Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021
[TBL] [Abstract][Full Text] [Related]
37. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients.
Sonnemann J; Gänge J; Pilz S; Stötzer C; Ohlinger R; Belau A; Lorenz G; Beck JF
BMC Cancer; 2006 Jul; 6():183. PubMed ID: 16834771
[TBL] [Abstract][Full Text] [Related]
38. Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species.
Alexandre J; Hu Y; Lu W; Pelicano H; Huang P
Cancer Res; 2007 Apr; 67(8):3512-7. PubMed ID: 17440056
[TBL] [Abstract][Full Text] [Related]
39. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
40. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
